FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952570650> ?p ?o ?g. }

• W2952570650 endingPage "706" @default.
• W2952570650 startingPage "699" @default.
• W2952570650 abstract "•Intelligent liver function testing utilises the smarter application of existing knowledge and technology. •Intelligent liver function testing increases diagnosis of liver disease by 43%, with diagnostic accuracy over 90%. •Intelligent liver function testing enables earlier identification of treatable liver disease. Background & Aims Liver function tests (LFTs) are frequently requested blood tests which may indicate liver disease. LFTs are commonly abnormal, the causes of which can be complex and are frequently under investigated. This can lead to missed opportunities to diagnose and treat liver disease at an early stage. We developed an automated investigation algorithm, intelligent liver function testing (iLFT), with the aim of increasing the early diagnosis of liver disease in a cost-effective manner. Methods We developed an automated system that further investigated abnormal LFTs on initial testing samples to generate a probable diagnosis and management plan. We integrated this automated investigation algorithm into the laboratory management system, based on minimal diagnostic criteria, liver fibrosis estimation, and reflex testing for causes of liver disease. This algorithm then generated a diagnosis and/or management plan. A stepped-wedged trial design was utilised to compare LFT outcomes in general practices in the 6 months before and after introduction of the iLFT system. Diagnostic outcomes were collated and compared. Results Of eligible patients with abnormal LFTs, 490 were recruited to the control group and 64 were recruited to the intervention group. The primary diagnostic outcome was based on the general practitioner diagnosis, which agreed with the iLFT diagnosis in 67% of cases. In the iLFT group, the diagnosis of liver disease was increased by 43%. Additionally, there were significant increases in the rates of GP visits after diagnosis and the number of referrals to secondary care in the iLFT group. iLFT was cost-effective with a low initial incremental cost-effectiveness ratio of £284 per correct diagnosis, and a saving to the NHS of £3,216 per patient lifetime. Conclusions iLFT increases liver disease diagnoses, improves quality of care, and is highly cost-effective. This can be achieved with minor changes to working practices and exploitation of functionality existing within modern laboratory diagnostics systems. Lay summary There is a growing epidemic of advanced liver disease, this could be offset by early detection and management. Checking liver blood tests (LFTs) should be an opportunity to diagnose liver problems, but abnormal results are often incompletely investigated. In this study we were able to substantially increase the diagnostic yield of the abnormal LFTs using the automated intelligent LFT system. With the addition of referral recommendations and management plans, this strategy provides optimum investigation and management of LFTs and is cost saving to the NHS. Liver function tests (LFTs) are frequently requested blood tests which may indicate liver disease. LFTs are commonly abnormal, the causes of which can be complex and are frequently under investigated. This can lead to missed opportunities to diagnose and treat liver disease at an early stage. We developed an automated investigation algorithm, intelligent liver function testing (iLFT), with the aim of increasing the early diagnosis of liver disease in a cost-effective manner. We developed an automated system that further investigated abnormal LFTs on initial testing samples to generate a probable diagnosis and management plan. We integrated this automated investigation algorithm into the laboratory management system, based on minimal diagnostic criteria, liver fibrosis estimation, and reflex testing for causes of liver disease. This algorithm then generated a diagnosis and/or management plan. A stepped-wedged trial design was utilised to compare LFT outcomes in general practices in the 6 months before and after introduction of the iLFT system. Diagnostic outcomes were collated and compared. Of eligible patients with abnormal LFTs, 490 were recruited to the control group and 64 were recruited to the intervention group. The primary diagnostic outcome was based on the general practitioner diagnosis, which agreed with the iLFT diagnosis in 67% of cases. In the iLFT group, the diagnosis of liver disease was increased by 43%. Additionally, there were significant increases in the rates of GP visits after diagnosis and the number of referrals to secondary care in the iLFT group. iLFT was cost-effective with a low initial incremental cost-effectiveness ratio of £284 per correct diagnosis, and a saving to the NHS of £3,216 per patient lifetime. iLFT increases liver disease diagnoses, improves quality of care, and is highly cost-effective. This can be achieved with minor changes to working practices and exploitation of functionality existing within modern laboratory diagnostics systems." @default.
• W2952570650 created "2019-06-27" @default.
• W2952570650 creator A5004579061 @default.
• W2952570650 creator A5012676770 @default.
• W2952570650 creator A5040458050 @default.
• W2952570650 creator A5047861906 @default.
• W2952570650 creator A5049524570 @default.
• W2952570650 creator A5049986054 @default.
• W2952570650 creator A5051452799 @default.
• W2952570650 creator A5054494206 @default.
• W2952570650 creator A5069879667 @default.
• W2952570650 creator A5077952215 @default.
• W2952570650 creator A5084827019 @default.
• W2952570650 date "2019-10-01" @default.
• W2952570650 modified "2023-10-14" @default.
• W2952570650 title "Intelligent liver function testing (iLFT): A trial of automated diagnosis and staging of liver disease in primary care" @default.
• W2952570650 cites W1976812315 @default.
• W2952570650 cites W2020582269 @default.
• W2952570650 cites W2032039690 @default.
• W2952570650 cites W2048172410 @default.
• W2952570650 cites W2064485284 @default.
• W2952570650 cites W2076751312 @default.
• W2952570650 cites W2081568260 @default.
• W2952570650 cites W2093397028 @default.
• W2952570650 cites W2110934550 @default.
• W2952570650 cites W2112258271 @default.
• W2952570650 cites W2115692333 @default.
• W2952570650 cites W2121509250 @default.
• W2952570650 cites W2121514783 @default.
• W2952570650 cites W2133275424 @default.
• W2952570650 cites W2146082049 @default.
• W2952570650 cites W2321700180 @default.
• W2952570650 cites W2387832857 @default.
• W2952570650 cites W2510968937 @default.
• W2952570650 cites W2528666530 @default.
• W2952570650 cites W2544613398 @default.
• W2952570650 cites W2578670173 @default.
• W2952570650 cites W2582997205 @default.
• W2952570650 cites W2767262086 @default.
• W2952570650 cites W2783968895 @default.
• W2952570650 cites W2790962315 @default.
• W2952570650 cites W2791547101 @default.
• W2952570650 cites W2804456129 @default.
• W2952570650 doi "https://doi.org/10.1016/j.jhep.2019.05.033" @default.
• W2952570650 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31226388" @default.
• W2952570650 hasPublicationYear "2019" @default.
• W2952570650 type Work @default.
• W2952570650 sameAs 2952570650 @default.
• W2952570650 citedByCount "40" @default.
• W2952570650 countsByYear W29525706502019 @default.
• W2952570650 countsByYear W29525706502020 @default.
• W2952570650 countsByYear W29525706502021 @default.
• W2952570650 countsByYear W29525706502022 @default.
• W2952570650 countsByYear W29525706502023 @default.
• W2952570650 crossrefType "journal-article" @default.
• W2952570650 hasAuthorship W2952570650A5004579061 @default.
• W2952570650 hasAuthorship W2952570650A5012676770 @default.
• W2952570650 hasAuthorship W2952570650A5040458050 @default.
• W2952570650 hasAuthorship W2952570650A5047861906 @default.
• W2952570650 hasAuthorship W2952570650A5049524570 @default.
• W2952570650 hasAuthorship W2952570650A5049986054 @default.
• W2952570650 hasAuthorship W2952570650A5051452799 @default.
• W2952570650 hasAuthorship W2952570650A5054494206 @default.
• W2952570650 hasAuthorship W2952570650A5069879667 @default.
• W2952570650 hasAuthorship W2952570650A5077952215 @default.
• W2952570650 hasAuthorship W2952570650A5084827019 @default.
• W2952570650 hasBestOaLocation W29525706502 @default.
• W2952570650 hasConcept C126322002 @default.
• W2952570650 hasConcept C126838900 @default.
• W2952570650 hasConcept C146357865 @default.
• W2952570650 hasConcept C151730666 @default.
• W2952570650 hasConcept C177713679 @default.
• W2952570650 hasConcept C2777075537 @default.
• W2952570650 hasConcept C2779134260 @default.
• W2952570650 hasConcept C2992208098 @default.
• W2952570650 hasConcept C512861765 @default.
• W2952570650 hasConcept C71924100 @default.
• W2952570650 hasConcept C86803240 @default.
• W2952570650 hasConceptScore W2952570650C126322002 @default.
• W2952570650 hasConceptScore W2952570650C126838900 @default.
• W2952570650 hasConceptScore W2952570650C146357865 @default.
• W2952570650 hasConceptScore W2952570650C151730666 @default.
• W2952570650 hasConceptScore W2952570650C177713679 @default.
• W2952570650 hasConceptScore W2952570650C2777075537 @default.
• W2952570650 hasConceptScore W2952570650C2779134260 @default.
• W2952570650 hasConceptScore W2952570650C2992208098 @default.
• W2952570650 hasConceptScore W2952570650C512861765 @default.
• W2952570650 hasConceptScore W2952570650C71924100 @default.
• W2952570650 hasConceptScore W2952570650C86803240 @default.
• W2952570650 hasIssue "4" @default.
• W2952570650 hasLocation W29525706501 @default.
• W2952570650 hasLocation W29525706502 @default.
• W2952570650 hasLocation W29525706503 @default.
• W2952570650 hasLocation W29525706504 @default.
• W2952570650 hasOpenAccess W2952570650 @default.
• W2952570650 hasPrimaryLocation W29525706501 @default.
• W2952570650 hasRelatedWork W1529138992 @default.
• W2952570650 hasRelatedWork W162290532 @default.

• next